Nutraceuticals in diabetes and metabolic syndrome

Cardiovascular Therapeutics

Volumn 28, Issue 4, 2010, Pages 216-226

  Davì, Giovanni ^a,b   Santilli, Francesca ^a,b   Patrono, Carlo ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Diabetes; Metabolic syndrome; Oxidative stress; Platelet activation; Vitamin

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ACARBOSE; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CHROMIUM; COLECALCIFEROL; CONJUGATED LINOLEIC ACID; ESTRADIOL; FLAVONOID; HEMOGLOBIN A1C; INTERLEUKIN 6; LIGNIN; LINOLEIC ACID; MAGNESIUM; METFORMIN; NUTRACEUTICAL; OLIGOSACCHARIDE; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPASE A2; PHYTOESTROGEN; POLYSACCHARIDE; RETINOID X RECEPTOR; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; VITAMIN D; ZINC; ANTIDIABETIC AGENT;

ANTIOXIDANT ACTIVITY; DIET SUPPLEMENTATION; DIETARY FIBER; EPIDEMIOLOGICAL DATA; EVIDENCE BASED PRACTICE; EXERCISE; FOOD COMPOSITION; GLUCOSE HOMEOSTASIS; HUMAN; LIPID PEROXIDATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTE ACTIVATION; VITAMIN INTAKE; WEIGHT CONTROL; ADULT; AGED; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG INTERACTION; EVIDENCE BASED MEDICINE; FEMALE; MALE; MIDDLE AGED; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954371707     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00179.x     Document Type: Review

References (60)

1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009 120 : 1640 1645.
2. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration?. Diabetologia 2009 52 : 1219 1226.
3. Position of the American Dietetic Association. Nutrient Supplementation. J Am Diet Assoc 2009 109 : 2073 2085.
4. Lamb RE, Goldstein BJ. Modulating an oxidative-inflammatory cascade: Potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int J Clin Pract 2008 62 : 1087 1095.
5. Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance. Diab Med 2005 22 : 674 668.
6. Ray A, Huisman MV, Tamsma JT, et al. The role of inflammation on atherosclerosis, intermediate and clinical cardiovascular endpoints in type 2 diabetes mellitus. Eur J Intern Med 2009 20 : 253 260.
7. Davì G, Falco A, Patrono C. Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal 2005 7 : 256 268.
8. Maritim AC, Sanders RA, Watkins JB III. Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol 2003 17 : 24 38.
9. Bartlett HE, Eperjesi F. Nutritional supplementation for type 2 diabetes: A systematic review. Ophthalmic Physiol Opt 2008 28 : 503 523.
10. Davì G, Chiarelli F, Santilli F, et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: Role of interleukin-6 and disease duration. Circulation 2003 107 : 3199 3203.
11. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ II. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990 87 : 9383 9387.
12. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007 357 : 2482 2494.
13. 2α and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation. Circulation 1999 99 : 224 229.
14. Franzini L, Ardigò D, Zavaroni I. Dietary antioxidants and glucose metabolism. Curr Opin Clin Nutr Metab Care 2008 11 : 471 476.
15. Riccioni G, Bucciarelli T, Mancini B, Corradi F, Di Ilio C, Mattei PA, D'Orazio N. Antioxidant vitamin supplementation in cardiovascular diseases. Ann Clin Lab Sci 2007 37 : 89 95.
16. Chen H, Karne RJ, Hall G, et al. High-dose oral vitamin C partially replenishes vitamin C levels in patients with type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. Am J Physiol Heart Circ Physiol 2006 290 : H137 H145.
17. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: The Physicians' Health Study II randomized controlled trial. JAMA 2008 300 : 2123 2133.
18. Patrignani P, Panara MR, Tacconelli S, et al. Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation 2000 102 : 539 545.
19. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL Nutrition Committee of the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Antioxidant vitamin supplements and cardiovascular disease. Circulation 2004 110 : 637 641.
20. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: Meta-analysis of randomised trials. Lancet 2003 361 : 2017 2023.
21. Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med 2004 164 : 1552 1556.
22. Miller III. ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005 142 : 37 46.
23. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysis. JAMA 2007 297 : 842 857.
24. House AA, Eliasziw M, Cattran DC, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: A randomized controlled trial. JAMA 2010 303 : 1603 1609.
25. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010 362 : 1675 1685.
26. Meagher EA, Barry OP, Lawson JA, Rokach J, FitzGerald GA. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 2001 285 : 1178 1182.
27. Block G, Jensen CD, Morrow JD, et al. The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level. Free Radic Biol Med 2008 45 : 377 384.
28. Roberts LJ II., Oates JA, Linton MF, et al. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med 2007 43 : 1388 1393.
29. Danescu LG, Levy S, Levy J. Vitamin D and diabetes mellitus. Endocrine 2009 35 : 11 17.
30. Palomer X, González-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 2008 10 : 185 197.
31. Draznin B, Sussman K, Kao M, Lewis D, Sherman N. The existence of an optimal range of cytosolic free calcium for insulin-stimulated glucose transport in rat adipocytes. J Biol Chem 1987 262 : 14385 14388.
32. The EURODIAB Substudy 2 Study Group. Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group. Diabetologia 1999 42 : 51 54.
33. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007 92 : 2017 2029. (Pubitemid 46997093)
34. Beecher GR. Overview of dietary flavonoids: Nomenclature, occurrence and intake. J Nutr 2003 133 : 3248S 3254S.
35. Jiang F, Dusting GJ. Natural phenolic compounds as cardiovascular therapeutics: Potential role of their anti-inflammatory effects. Curr Vasc Pharmacol 2003 1 : 135 156.
36. García-Lafuente A, Guillamón E, Villares A, Rostagno MA, Martínez JA. Flavonoids as anti-inflammatory agents: Implications in cancer and cardiovascular disease. Inflamm Res 2009 58 : 537 552.
37. Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB, de Gaetano G. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 2002 105 : 2836 2844.
38. Di Castelnuovo A, Costanzo S, Bagnardi V, Donati MB, Iacoviello L, de Gaetano G. Alcohol dosing and total mortality in males and females: An updated meta-analysis of 34 prospective studies. Arch Intern Med 2006 166 : 2437 2445.
39. Hertog MGL, Kromhout D, Aravanis C, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med 1995 155 : 381 386.
40. Knekt P, Kumpulainen J, Jarvinen R, et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002 76 : 560 568.
41. Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, Jacobs DR Jr. Flavonoid intake and cardiovascular disease mortality: A prospective study in postmenopausal women. Am J Clin Nutr 2007 85 : 895 909.
42. Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA. Tea consumption and mortality after acute myocardial infarction. Circulation 2002 105 : 2476 2481.
43. Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: A meta-analysis of randomized controlled trials. Am J Clin Nutr 2008 88 : 38 50.
44. Valmadrid CT, Klein R, Moss SE, Klein BE, Cruickshanks KJ. Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus. JAMA 1999 282 : 239 246.
45. Solomon CG, Hu FB, Stampfer MJ, et al. Moderate alcohol consumption and risk of coronary heart disease among women with type 2 diabetes mellitus. Circulation 2000 102 : 494 499.
46. Ajani UA, Gaziano JM, Lotufo PA, Liu S, Hennekens CH, Buring JE, Manson JE. Alcohol consumption and risk of type 2 diabetes mellitus among US male physicians. Arch Intern Med 2000 160 : 1025 1030.
47. McCarty MF. Nutraceutical resources for diabetes prevention - an update. Med Hypotheses 2005 64 : 151 158.
48. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002 359 : 2072 1077.
49. Kris-Etherton PM, Harris WS, Appel LJ AHA Nutrition Committee. American Heart Association. Omega-3 fatty acids and cardiovascular disease: New recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003 23 : 151 152.
50. Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HA. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 2007 50 : 1593 1602.
51. Fedor D, Kelley DS. Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 2009 12 : 138 146.
52. Lau FC, Bagchi M, Sen CK, Bagchi D. Nutrigenomic basis of beneficial effects of chromium(III) on obesity and diabetes. Mol Cell Biochem 2008 317 : 1 10.
53. Althuis MD, Jordan NE, Ludington EA, Wittes JT. Glucose and insulin responses to dietary chromium supplements: A meta-analysis. Am J Clin Nutr 2002 76 : 148 155.
54. American Diabetes Association. Nutrition recommendations and interventions for diabetes (Position Statement). Diabetes Care 2007 30 : S48 S65.
55. Bo S, Pisu E. Role of dietary magnesium in cardiovascular disease prevention, insulin sensitivity and diabetes. Curr Opin Lipidol 2008 19 : 50 56.
56. Evans JR, Henshaw K. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev 2008 1:CD000253.
57. Singh U, Jialal I. Alpha-lipoic acid supplementation and diabetes. Nutr Rev 2008 66 : 646 657.
58. Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: Current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999 107 : 421 430.
59. Cederroth CR, Nef S. Soy, phytoestrogens and metabolism: A review. Mol Cell Endocrinol 2009 304 : 30 42.
60. Papathanasopoulos A, Camilleri M. Dietary fiber supplements: Effects in obesity and metabolic syndrome and relationship to gastrointestinal functions. Gastroenterology 2010 138 : 165 172.